Citigroup
GPCR icon

Citigroup’s Structure Therapeutics GPCR Stock Holding History

Citigroup’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$520K Sell
9,680
-10,814
-53% -$478K ﹤0.01% 3878
2026
Q1 		$988K Buy
20,494
+13,159
+179% +$901K ﹤0.01% 3129
2025
Q4 		$510K Buy
7,335
+5,879
+404% +$240K ﹤0.01% 3562
2025
Q3 		$40.8K Sell
1,456
-144
-9% -$2.87K ﹤0.01% 4558
2025
Q2 		$33.2K Sell
1,600
-103,375
-98% -$2.27M ﹤0.01% 4944
2025
Q1 		$1.82M Buy
104,975
+30,891
+42% +$757K ﹤0.01% 2787
2024
Q4 		$2.01M Buy
74,084
+72,533
+4,677% +$2.57M ﹤0.01% 2818
2024
Q3 		$68.1K Buy
1,551
+103
+7% +$3.98K ﹤0.01% 4920
2024
Q2 		$56.9K Buy
1,448
+1,095
+310% +$45K ﹤0.01% 4506
2024
Q1 		$15.1K Sell
353
-16,327
-98% -$688K ﹤0.01% 5108
2023
Q4 		$680K Buy
16,680
+16,555
+13,244% +$949K ﹤0.01% 3165
2023
Q3 		$6.3K Buy
+125
New +$4.03K ﹤0.01% 4661

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Citigroup's GPCR Position: Q2 2026 in Review

Citigroup reduced its Structure Therapeutics (GPCR) stake by 53% in Q2 2026, selling an estimated $478K and leaving 9,680 shares worth $520K. The position accounts for ﹤0.01% of the portfolio, ranked #3878.

Citigroup first reported a position in GPCR in Q3 2023 and has held it in 12 quarters since. The position peaked at $2.01M in Q4 2024. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Citigroup held 9,680 shares of Structure Therapeutics worth $520K as of Q2 2026.
  • Citigroup sold 10,814 Structure Therapeutics shares in Q2 2026, an estimated $478K.
  • Structure Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3878 holding.
  • Citigroup first reported a position in Structure Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Citigroup's Structure Therapeutics position peaked at $2.01M in Q4 2024.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.